Bigfish Bio-tech Received $1.4 Million in Pre-Series A Financing

According to 36KR, on May 17, 2019, molecular testing equipment company Bigfish Bio-tech just received 1.4 million dollars in pre-Series A financing. This round of financing was led by Longly Capital and followed by Yilai Capital and Eagles Fund. This round of funds will be used for the research and development of new products such as molecular POCT and construction of the supply chain.

After half a year, Bigfish's basic molecular testing products have been commercialized and earned nearly 5 million RMB in sales in the second half year of 2018. User groups have also expanded from public security to animal husbandry, pets, disease control, third-party inspections, hospitals and universities.

Bigfish expects to complete the prototype of molecular POCT in next month. After the product is launched in the second half of this year, it can greatly reduce the technology and cost of molecular POCT, replacing the old and less reliable detection methods, and bring the molecular POCT in more fields. Right now, the company has received At present, we have received many orders from companies and organizations such as public security, animal husbandry, pets, medical examinations and disease control.

The basic molecular testing and molecular POCT testing products are expected to earn 40 million RMB in sales in 2019.

Longly Capital is an investment company that mainly investing in early venture capital, focusing on industries with potential in China, like health industries and online industries. 

A Chinese venture capital and asset management company.

Eagles Fund is a diversified angel fund and family fund in China.